All news

Insight Molecular Diagnostics announces proposed public offering

Alpha Vantage · GlobeNewswire · · AI-summarised by FinFlash

Insight Molecular Diagnostics Inc. announced an underwritten public offering of common stock or pre-funded warrants, with the underwriter granted a 15% option for additional shares. Net proceeds are earmarked for working capital and general corporate purposes, including transplantation research and development. The offering is subject to market conditions, with no guarantee of completion, size or terms.

Read original source

IMDX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.